Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
July 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 09, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Completes Acquisition of Escient Pharmaceuticals
May 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 21, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
May 14, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.